Monopar Therapeutics — Director's Dealing 2020

Feb 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2020-01-31

Reporting Person: STARR CHRISTOPHER M (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-31	Restricted Stock Units	$0	A	1289	Acquired		Common Stock (1289)	Direct
2020-01-31	Stock Options	$14.35	A	5646	Acquired	2030-01-31	Common Stock (5646)	Direct

Footnotes

F1: Restricted stock units vest 25% on April 1, 2020, 25% on July 1, 2020, 25% on October 1, 2020, and 25% on January 1, 2021.

F2: Stock options vest 25% on March 31, 2020, 25% on June 30, 2020, 25% on September 30, 2020, and 25% on December 31, 2020.